Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) has announced positive topline results from the SURMOUNT-1 study, a 176-week trial, which is the longest completed study of... ByInvesting.com ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

That leaves Lilly hoping for a strong readout from its phase 3 TRAILBLAZER-ALZ 2 study, with top-line results due in the second quarter, that will form the basis of its full marketing application.